Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Metabolic Derangements in Acute Heart Failure Syndrome

This study has been terminated.
(Project not initiated)
Sponsor:
Information provided by:
The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT00682175
First received: May 20, 2008
Last updated: March 25, 2009
Last verified: March 2009
History of Changes
  Purpose

To determine the association of both neurohormonal and hemodynamic alterations associated with metabolic abnormalities in acute heart failure syndrome.


Condition Intervention
Congestive Heart Failure
 Other: Observational

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Metabolic Derangements in Acute Heart Failure Syndrome

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by The Cleveland Clinic:

Biospecimen Retention:   Samples Without DNA

serum, plasma
Estimated Enrollment: 100
Study Start Date: May 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Observation
Adult (age > 18 yrs) patients admitted to the Heart Failure Intensive Care Unit with Acute Heart Failure Syndrome requiring placement of a Pulmonary Artery catheter for hemodynamically guided therapy.
 Other: Observational
Pulmonary Artery pressure (PA), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and cardiac index (CI). This data will be collected after 24 ± 2 and 48 ± 2 hours of standard heart failure therapy

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Adult (age > 18 yrs) patients admitted to the Heart Failure Intensive Care Unit (H22) with Acute Heart Failure Syndrome (AHFS) requiring placement of a Pulmonary Artery catheter for hemodynamically guided therapy.

Criteria

Inclusion Criteria:

  • Adult (age > 18 yrs) patients admitted to the Heart Failure Intensive Care Unit (H22) with Acute Heart Failure Syndrome (AHFS) requiring placement of a Pulmonary Artery catheter for hemodynamically guided therapy.

Exclusion Criteria:

  • History of Congenital Heart Disease.
  • Acute HF in the setting of acute myocardial infarction.
  • Severe Anemia
  • Patients listed for cardiac transplantation.
  • Terminal Malignancy, AIDS or CNS disease.
  • Concomitant sepsis, ARDS, trauma, aortic dissection, or pericardial tamponade
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00682175

Sponsors and Collaborators
The Cleveland Clinic
Investigators
Principal Investigator: George Sokos, MD The Cleveland Clinic
  More Information

No publications provided

Responsible Party: George Sokos, MD, Cleveland Clinic Foundation
ClinicalTrials.gov Identifier: NCT00682175     History of Changes
Other Study ID Numbers: 08-169
Study First Received: May 20, 2008
Last Updated: March 25, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by The Cleveland Clinic:
Congestive Heart Failure

Additional relevant MeSH terms:
Heart Failure
Metabolic Diseases
Cardiovascular Diseases
Heart Diseases

ClinicalTrials.gov processed this record on March 03, 2015